4-(1,1-二甲基乙基)-2-甲基喹啉 | 152536-61-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-(1,1-二甲基乙基)-2-甲基喹啉
• 英文名称: 4-(tert-butyl)-2-methylquinoline
• 英文别名: 4-Tert-butyl-2-methylquinoline
• CAS: 152536-61-3
• 化学式: C₁₄H₁₇N
• 分子量: 199.296
• InChiKey: QLEFAUJNQOMRKW-UHFFFAOYSA-N

物化性质

• 沸点：
  298.3±9.0 °C(Predicted)
• 密度：
  0.997±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(1,1-二甲基乙基)-2-甲基喹啉 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以56%的产率得到4-叔丁基-2-甲基-1,2,3,4-四氢喹啉
  参考文献：
  名称：

  tert-Butylation of Quinolinium Cations and Quinoline N-Oxides by tert-Butylmercury Halides

  摘要：

  In the presence of t-BuHgCl/KI the radical cations formed by the addition of tert-butyl radicals to C-2 of the quinolinium cation react in Me(2)SO by proton loss followed by one-electron oxidation (1a, R = H, Me, Cl). For the N-methyl, or N-methoxyquinolinium cations proton loss is not observed and the radical cations react by one-electron reduction (1b, R = Me, Cl; Ic, R = Me), With quinoline N-oxide and its 4-substituted derivatives the C-2 adduct radicals (1d, R = H, Me, Cl) are deprotonated by DABCO to yield after one-electron oxidation the 2-tert-butylquinoline N-oxides. The adduct radical cations formed by t-Bu(.) addition at the C-4 of quinolinium ions 2 seldom lose the C-4 proton but react by reduction, hydration, or in the case of 2-chloroquinoline N-oxide, dimerization. The loss of the proton from the 2-adducts 1 but not from the 4-adducts 2 seems to be stereoelectronic in origin. With N-methylquinolinium cation the addition of t-Bu(.) occurs selectively (>90%) at C-4 in contrast to the low selectivity observed in addition to quinolinium ion itself. However, with N-methoxyquinolinium perchlorate the major reaction products (70-90%) result from the addition of t-Bu(.) at C-2.

  DOI：

  10.1021/jo00122a013
• 作为产物：
  描述：

  2-甲基喹啉 、 三甲基乙酸 在 dipotassium peroxodisulfate 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 16.0h， 以61%的产率得到4-(1,1-二甲基乙基)-2-甲基喹啉
  参考文献：
  名称：

  使用羧酸对杂芳烃和1,4-喹啉进行金属，光催化剂和无光后期C–H烷基化

  摘要：

  与公认的惯例相反，这项工作表明，Minisci型C–H烷基化不需要任何金属，光催化剂，光或易于获得的廉价羧酸的预官能化，即可在温和条件下顺利进行。这些温和的条件可用于复杂分子的后期烷基化，包括在光催化条件下降解的药物化合物和光敏化合物。

  DOI：

  10.1021/acs.orglett.8b02988

文献信息

• Hepatitis C virus inhibitors
  申请人：D'Andrea Stanley

  公开号：US20070099825A1

  公开（公告）日：2007-05-03

  Macrocyclic peptides are disclosed having the general formula: wherein R′, R 3 , R 3′ , R 4 , R 6 , X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  大环肽被公开，具有一般的公式： 其中R'，R3，R3'，R4，R6，X，Q和W被描述。还公开了包含该化合物的组合物以及使用该化合物抑制HCV的方法。
• PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS
  申请人：Bergmann John E.

  公开号：US20080300240A1

  公开（公告）日：2008-12-04

  Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R 1 , R 2 , R 3 , R 4 , R 5 , A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE 10 in a warm-blooded animal in need of the same.

  抑制PDE10的化合物已被披露，对治疗包括（但不限于）精神病、焦虑、运动障碍和/或神经系统疾病（如帕金森病、亨廷顿病、阿尔茨海默病、脑炎、恐惧症、癫痫、失语症、贝尔氏面瘫、脑瘫、睡眠障碍、疼痛、抽动症、精神分裂症、妄想症、药物诱发的精神病和恐慌以及强迫症）多种疾病具有用途。这些化合物具有一般结构： 其中m、n、p、x、R、R1、R2、R3、R4、R5、A和B在此定义，包括药学上可接受的盐、立体异构体、溶剂合物或其前药。还披露了含有本发明化合物的组合物，与药学上可接受的载体结合，以及与使用这些化合物抑制需要同样的PDE10的温血动物相关的方法。
• Substituted Benzamide Compounds
  申请人：Reich Melanie

  公开号：US20120071461A1

  公开（公告）日：2012-03-22

  Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

  对应于式(I)的取代苯甲酰胺化合物，其中R5、R6、R7、R8、a、b、c、d、t、D和X具有定义的含义，其制备方法，包括这些化合物的药物组合物，以及使用这些化合物治疗疼痛和其他至少部分通过激肽酶1受体介导的疾病的方法。
• Synthesis of Functionalized Quinolines through a Reaction of Amides and Alkynes Promoted by Triflic Anhydride/Pyridine
  作者：Lian-Hua Li、Zhi-Jie Niu、Yong-Min Liang

  DOI：10.1002/chem.201703832

  日期：2017.11.2

  A concise, novel and flexible metal‐free single step to synthesize functionalized quinolines is reported. Triflic anhydride‐mediated (Tf2O) activation of amides is discussed in the presence of pyridine to offer strong electrophiles, thereby showcasing excellent productivity, high regio‐ and chemoselectivity, and widely tolerable substrates. This approach provides a straightforward and efficient way

  据报道，一种简洁，新颖且灵活的无金属一步法可以合成官能化喹啉。在吡啶的存在下讨论了三氟甲磺酸酐介导的（Tf 2 O）活化酰胺，以提供强亲电试剂，从而显示出优异的生产率，高区域选择性和化学选择性以及可广泛耐受的底物。该方法提供了构建氮杂杂环结构的直接有效的方法。
• MASP-2 INHIBITORS AND METHODS OF USE
  申请人：Omeros Corporation

  公开号：US20210171461A1

  公开（公告）日：2021-06-10

  The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

  本公开提供了具有MASP-2抑制活性的化合物，这些化合物的组合物，以及制备和使用这些化合物的方法。